TCON TRACON Pharmaceuticals Inc.: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
TRACON Pharmaceuticals (TCON) is currently winding down its business and liquidating assets due to the cessation of medical trials. The company previously ensured the strict transportation of biomaterials to protect patients within the scope of these studies. This price chart, which serves as confirmation of the market valuation where EV/EBITDA stands at , illustrates the position of the developer of targeted methods for combating rare types of sarcomas for oncology centers.
Comprehensive metric breakdowns and analytics for traconpharma.com (TCON)
- market price and analyst price targets:
- company stock capitalization data:
- book value of equity indicators:
- company total debt and liquidity indicators:
Total Debt to Capital TRACON Pharmaceuticals|TCON - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital TRACON Pharmaceuticals, Inc.|TCON - Company Aggregate Debts|Debt to Book Capitalization Ratio TRACON Pharmaceuticals, Inc|TCON - Company Long-Term Loans and Borrowings|Company Short-Term Debt TRACON Pharmaceuticals|Quick Ratio traconpharma.com
- net income and valuation multiples indicators:
TCON - Net Profit|Projected Future Earnings TRACON Pharmaceuticals|TCON - Price to Earnings Ratio|Forward P/E Multiple TRACON Pharmaceuticals|TCON - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio TRACON Pharmaceuticals, Inc|TCON - Operating profit EBITDA|Net earnings per share for the last 12 months TRACON Pharmaceuticals|TCON - Earnings per share for the last four quarters|Quarterly EPS earnings growth traconpharma.com|TCON - Expected net earnings per share growth this year|Earnings growth forecast for next year TRACON Pharmaceuticals
Fundamental company analysis:TCON (TRACON)
The EV/EBITDA ratio trajectory determines the market value of TRACON Pharmaceuticals (TCON), accounting for net debt relative to operating profit. This indicator measures the business value by considering the impact of borrowing costs and the tax burden on total capitalization. For a biopharmaceutical company investing in antibody development, this multiple serves as a marker of capital structure stability prior to the drug commercialization stage.
Key competitors
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization tempus.com TEM|Qiagen Corp (QGEN) - Company Value to EBITDA|IONS - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|RGEN (repligen.com) - Enterprise Value to Operating Income Before Depreciation|RNA (Avidity Biosciences, Inc.) - Enterprise Value to EBITDA Ratio|CRISPR Therapeutics Inc - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Sema4|Ultragenyx Corp - Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple BEAM|SRPT (sarepta.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple TWST (Twist Bioscience, Inc.)|EV/EBITDA Multiple 10x Genomics Inc TXG|NTLA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation STOK (Stoke Corp)|BioLife Solutions, Inc. (BLFS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio wavelifesciences.com|MAZE (Maze Therapeutics) - EV/EBITDA Multiple|EV/EBITDA Multiple Sionna Therapeutics, Inc.|EV/EBITDA Multiple PRME|Enterprise Value to EBITDA Ratio Taysha Corp TSHA|EV/EBITDA Multiple QURE (uniQure N.V.)|meiragtx.com (MGTX) - Company Value to EBITDA|RGNX: Enterprise Value to EBITDA Ratio|SLDB - EV/EBITDA Multiple|OCGN (Ocugen Corp) - Enterprise Value to EBITDA Ratio|PACB: Enterprise Value to Operating Income Before Depreciation Ratio|BNTC (Benitec Biopharma Inc.) - EV/EBITDA Multiple|designtx.com (DSGN) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple RCKT|Enterprise Value to EBITDA Ratio 4DMT FDMT|EV/EBITDA Multiple LXEO (Lexeo Therapeutics, Inc.)|EV/EBITDA Multiple Korro Bio Inc. KRRO|EDIT - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|SLN: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|proqr.com (PRQR) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CDXS - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio SGMO|NAUT (Nautilus Biotechnology Inc) - Enterprise Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple MGX|Enterprise Value to EBITDA Ratio precisionbiosciences.com DTIL|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Generation Bio GBIO|Boundless Bio Inc. (BOLD) - Company Value to EBITDA|XCUR - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|IMNN (Imunon, Inc.) - Enterprise Value to Operating Income Before Depreciation|PHIO: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation MBIO|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization TransCode Therapeutics Inc.|Enterprise Value to Operating Income Before Depreciation BNGO (Bionano)|EV/EBITDA Multiple APDN|EV/EBITDA Multiple bluebird bio, Inc (BLUE)|ImmunoPrecise Antibodies Ltd. - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio OMGA (omegatherapeutics.com)|OMIC - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation RGLS (Regulus Therapeutics, Inc.)|SYRS: EV/EBITDA Multiple|Telesis Bio, Inc (TBIO) - EV/EBITDA Multiple|UBX (Unity Biotechnology) - EV/EBITDA Multiple
